Eiko Lifesciences Ltd
Eiko Lifesciences Ltd (EIKO) last traded at ₹48.3, a market capitalisation of ₹70.8 crore, on a P/E of 14.4. Over the past 52 weeks the stock has ranged between ₹44.8 and ₹64.4. Eiko Lifesciences Ltd last reported results for the quarter ended Jun 2026, with sales of ₹16.75 crore and net profit of ₹1.51 crore. Eiko Lifesciences Ltd’s annual general meeting is scheduled for 22 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
Eiko Lifesciences Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Eiko Lifesciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹16.75 cr, up 56.4% from ₹10.71 cr a year earlier. Net profit was ₹1.51 cr, up 36.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 8.16 | 7.49 | 11.27 | 10.71 | 11.67 | 11.98 | 18.34 | 16.75 |
| Expenses | 7.73 | 6.86 | 9.95 | 9.2 | 9.9 | 10.1 | 16.08 | 14.82 |
| Operating profit | 0.43 | 0.63 | 1.32 | 1.51 | 1.77 | 1.88 | 2.26 | 1.93 |
| OPM % | 5.27% | 8.41% | 11.71% | 14.10% | 15.17% | 15.69% | 12.32% | 11.52% |
| Other income | 0.13 | 0.12 | 0.64 | 0.27 | 0.3 | 0.35 | 0.13 | 0.45 |
| Interest | 0.04 | 0.03 | 0.07 | 0.05 | 0.1 | 0.07 | 0.12 | 0.13 |
| Depreciation | 0.16 | 0.16 | 0.25 | 0.25 | 0.26 | 0.26 | 0.25 | 0.25 |
| Profit before tax | 0.36 | 0.56 | 1.64 | 1.48 | 1.71 | 1.9 | 2.02 | 2 |
| Tax % | 27.78% | 25.00% | 23.78% | 25.00% | 24.56% | 24.74% | 25.74% | 24.50% |
| Net profit | 0.28 | 0.42 | 1.25 | 1.11 | 1.29 | 1.43 | 1.5 | 1.51 |
| EPS (₹) | 0.22 | 0.33 | 0.84 | 0.66 | 0.79 | 0.88 | 0.91 | 0.91 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Eiko Lifesciences Ltd annual results
| ₹ crore | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
| Sales | 2.36 | 4.27 | 10.4 | 37.66 | 52.71 | 58.74 |
| Operating profit | 0.38 | -0.68 | -4.51 | 2.77 | 7.43 | 7.84 |
| OPM % | 16.10% | -15.93% | -43.37% | 7.36% | 14.10% | 13.35% |
| Net profit | 0.2 | -0.78 | -3.62 | 2.32 | 5.33 | 5.73 |
| EPS (₹) | 0.31 | -0.69 | -2.98 | 1.86 | 3.14 | 3.49 |
TTM is the trailing twelve months to the most recent quarter.
Eiko Lifesciences Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 56%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 102%
- 10 Years
- %
- 5 Years
- -12%
- 3 Years
- -8%
- 1 Year
- -10%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- 7%
Eiko Lifesciences Ltd shareholding pattern
Promoters held 39.91% at Jun 2026, up from 36.74% at Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 24.40% | 31.27% | 36.23% | 36.74% | 37.17% | 37.17% | 39.91% | 39.91% |
| Public | 75.59% | 68.73% | 63.78% | 63.26% | 62.81% | 62.83% | 60.09% | 60.09% |
| No. of shareholders | 3,140 | 3,456 | 3,336 | 3,322 | 3,150 | 3,092 | 2,969 | 3,019 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is Eiko Lifesciences Ltd’s AGM?
Eiko Lifesciences Ltd’s annual general meeting is scheduled for 22 Sept 2026.
- AGMConvening of 49th Annual General Meeting
See the full results calendar for every Indian company reporting in the next 30 days.
Eiko Lifesciences Ltd corporate filings
- Newspaper Advertisement for 49th Annual General Meeting (AGM) of the Company scheduled to be held on Tuesday, 22nd day of September, 2026 at 04:00 P.M. IST through Video Conference / Other ....Company Updatelow impact
Cruxal's analysis: Eiko Lifesciences Limited has issued a formal disclosure regarding its 49th Annual…
Read the full analysis - Pursuant to provision of Regulations 30 and 34 of the SEBI LODR Regulations, 2015, we wish to inform that the 49th Annual General Meeting of the Company will be held on Tuesday, 22nd day ....Otherslow impact
Cruxal's analysis: Eiko Lifesciences has announced that its 49th Annual General Meeting will be held on…
Read the full analysis - Pursuant to provision of Regulations 30 and 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the 49th Annual General Meeting of ....AGM/EGMmedium impact
Cruxal's analysis: Eiko LifeSciences Limited has issued a notice for its 49th Annual General Meeting…
Read the full analysis - The Meeting of the Board of Directors of the Company held today i.e., on Monday, 24th August, 2026, Board, inter-alia, considered the following: 1. Noting of resignation of Ms. Hasti ....Company Updatelow impact
Cruxal's analysis: Eiko Lifesciences Limited has formally notified the exchange regarding the resignation of…
Read the full analysis - Appointment of Mr. Suraj Mahadev Gaikwad (DIN: 11159369) as Additional Director (Independent and Non-Executive) of the Company to hold the office up to the date of the ensuing Annual General ....Company Updatelow impact
Cruxal's analysis: Eiko Lifesciences Limited has announced the appointment of Mr. Suraj Mahadev Gaikwad as…
Read the full analysis - Meeting of the Board of Directors of the Company held today i.e., on Monday, 24th August, 2026, Board, inter-alia, considered the following: 1. Noting of resignation of Ms. Hasti Doshi ....Otherslow impact
Cruxal's analysis: Eiko LifeSciences Limited has announced a board-level transition involving the…
Read the full analysis - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015Company Updatelow impact
Cruxal's analysis: Eiko Lifesciences Ltd has filed a routine disclosure under Regulation 30 of the SEBI…
Read the full analysis - Disclosure of Conversion of 305000 Warrants into Equity Shares belonging to Promoter and Non Promoter CategoryCompany Updatelow impact
Cruxal's analysis: Eiko Lifesciences has completed the allotment of 305,000 equity shares following the…
Read the full analysis - Pursuant to Regulations 30 and 47 read with Schedule III of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, The copy of newspaper publication in the following ....Company Updatelow impact
Cruxal's analysis: Eiko Lifesciences has fulfilled regulatory requirements under SEBI LODR by publishing its…
Read the full analysis - Pursuant to the Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), and amendments ....Board Meetinghigh impact
Cruxal's analysis: Eiko LifeSciences Limited reported consolidated revenue from operations of 16.75 crore…
Read the full analysis - Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve The Unaudited Standalone ....Board Meetinglow impact
Cruxal's analysis: Eiko LifeSciences Limited has issued a formal intimation regarding a Board of Directors…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Eiko Lifesciences Ltd
Cruxal reads every Eiko Lifesciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.